any new and emerging diseases are zoonotic, meaning they can be transmitted from animals to humans. 1 The One Health approach addresses better control of these pathogens by recognizing connections between the animal, human and environmental domains.
Symptoms of primary illness begin 3-10 days after infection with E. coli O157 bacteria and range from diarrhea and fever to severe bloody diarrhea to Haemolytic Uremic Syndrome and death. 2 Longterm studies following patients infected with E. coli O157 have documented secondary illnesses due to hypertension, cardiovascular and kidney disease as well as arthritis. 3 Many steps have been taken along the farm-to-fork continuum to reduce the risk of infection from E. coli O157, such as consumer education about food handling practices, better retail and transport refrigeration, test and hold procedures at the processing stage, and hide washes and carcass pasteurization during harvest. Currently, little is being done on the farm to reduce E. coli O157 prevalence prior to harvest. As part of a multiple-hurdle approach, more can be done at this stage to further reduce the public health risk of illness due to E. coli O157. Recent developments in cattle vaccination against E. coli O157 may offer a solution.
E. coli O157 colonizes in the intestines of cattle and has not been associated with clinical disease of the carrier animal. 2 The bacterium is shed in the feces, and manure from beef and dairy farms, used as a fertilizer for crops, is a source of contamination for the general environment as well as for surface and ground water.
Epidemiological studies indicate there is an association between higher rates of E. coli O157 human infection and areas associated with higher cattle densities. 4 A review of existing studies demonstrates prevalence rates of animals testing positive for E. coli O157 ranging from 9% to 88%. This wide range exists both within and between herds and results from several factors, such as season (prevalence is higher in summer than in winter), environmental conditions, and conditions in the feedyard. 2, 5 The United States Department of Agriculture (USDA) Food Safety Inspection Service Risk Modelers studied the relationship among seasonal occurrence of E. coli O157 in cattle, ground beef, and human illness. 6 Their investigation supports the theory that an increased shedding of E. coli O157 by cattle in the summer season is associated with an increased prevalence of this organism in ground beef and a corresponding increase in number of human illnesses.
Published data show immunization of cattle to decrease the E. coli O157 seasonal prevalence spike from April to October. 5 Data also show that cattle vaccination decreases shedding of E. coli O157, which reduces the risk of human illness. 6 By reducing colonization and shedding, vaccination also reduces the probability for environmental transmission of E. coli O157 within commercial farm operations, thus gradually limiting the re-infection cycle within the herd. 7 Modeling by Matthews et al. predicts that interventions aimed at preventing high bacterial loads could be highly effective strategies for reducing prevalence of E. coli O157. 8 In 2008, the Canadian Food Inspection Agency (CFIA) fully licensed a vaccine for immunization of healthy cattle as an aid in the reduction of shedding of E. coli O157. To reduce the public health risk associated with exposure to E. coli O157, vaccination of cattle across the various industry segments (beef, dairy, organic, cow-calf) should be implemented. Such an approach is supported by results of a recent study indicating that cattle vaccination is considered the most effective measure to reduce human exposure to E. coli O157. 9 This can be completed concurrently with routine vaccination practices related to herd health management.
The USDA Food Safety Inspection Service investigated the economic outcomes of pre-harvest vaccination strategies based on vaccine efficacy and coverage. 5 The model investigated the economic break-even point, factoring in multiple prices per dose of vaccine, vaccine efficacy and herd immunity levels. Withee et al. determined that, depending on vaccine efficacy, it would be a costeffective intervention in preventing E. coli O157 human illness, at a price per unit between $2.29 and $9.14 USD. 5 Similarly, using quantitative risk assessment methodology, Smith et al. investigated the public health risks in Canada associated with E. coli O157 contamination in ground beef, non-intact beef (tenderized) and intact beef. 10 The authors focused on risk reduction arising from the use of various combinations of pre-harvest and processing interventions and its impact on public health. Based on their analysis, the most effective approach is to include vaccination of cattle using the Canadian licensed product as a pre-harvest step in conjunction with multiple interventions throughout the chain. The current risk reduction scenario is based on the use of pre-harvest interventions, presented in Table 1 . Vaccination of cattle with the product licensed by CFIA provided maximal risk reduction. According to Smith et al., the average number of illnesses per million servings of cooked ground beef would be reduced from 8 with current practices to less than 1 by combining pre-harvest vaccination of cattle with the product licensed by CFIA together with enhanced post-harvest processing practices.
Ellis-Iversen et al. found that most UK farmers accepted ownership of their role in food safety, and that producers with on-farm control measures associated these actions with consumer demand and profitability. 11 Younger farmers and larger producers were more likely to believe financial responsibility to be an industry-wide duty; and the veterinarian is typically considered the preferred motivator.
A survey indicated that Canadian producers believe E. coli O157 food-borne illnesses and beef recalls are a genuine threat to the health of their industry.
12 A majority of producers expressed sensitivity about the cost of the vaccine, which is approximately $3 per dose. Producers, however, also expressed an overwhelming willingness (88%) to vaccinate their cattle, provided the vaccine was provided at no cost or if they received offsetting revenue.
Various Canadian industry associations and government departments, such as The Beef Value Chain Roundtable and the Association of Bovine Veterinarians, have expressed support for strategies that eliminate or reduce E. coli O157. 13 The Government Standing Committees of Finance and Agriculture have likewise recommended the funding, development and implementation of a program designed to ensure the removal or reduction of E. coli from the Canadian food chain.
14 Guidance has been issued by the USDA's Food Safety Inspection Service, recommending that slaughter facilities obtain cattle that have received one or more pre-harvest interventions to reduce shedding of E. coli O157. 15 An alternate approach is being considered in Sweden, where experts are developing a national on-farm E. coli O157 control program. 1 Globally, the contamination of meat, vegetables, fruits and water as a result of exposure to E. coli O157 from livestock manure is a threat to public health. Preventing infections in people requires control measures at all stages of the food chain, from agricultural production on the farm to the processing, manufacturing and preparation of foods in commercial establishments and in the home. Cattle are routinely immunized against common bovine pathogens to prevent infection and disease. Incorporation of an additional vaccine to reduce a public health risk would easily fit into existing herd health management protocols within all production systems. The majority of reported outbreaks with verotoxigenic E. coli are due to the O157 serotype. Evidence indicates that other serotypes such as O26, O111, O103, O121, O45 and O145 contribute to human illness. 2 Data clearly show that vaccination of cattle with the E. coli O157 Type III protein or the SRP vaccine decreases E. coli O157 shedding. To the best of the authors' knowledge, data demonstrating efficacy of either vaccine on non-O157 serotypes in cattle is not yet available. 
